ReviewCurrent opinion in supportive and palliative care2026
Recent advances in autoantibody-mediated pain.
Review in Current opinion in supportive and palliative care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewRecent studies increasingly support a role for autoantibodies in selected chronic pain disorders. This review examines current evidence linking autoantibodies to nociceptive sensitisation and neuroimmune dysfunction across these conditions. RECENT
findingsExperimental and clinical evidence links autoantibodies to altered neuronal excitability, neuroimmune activation, and pain hypersensitivity, particularly within the dorsal root ganglion and spinal sensory circuits. Emerging work further suggests that pathogenicity and treatment responsiveness depend on factors beyond antibody specificity alone, including tissue injury, inflammatory context, and downstream immune signalling mechanisms. SUMMARY: Autoimmune pain disorders appear to comprise biologically heterogeneous neuroimmune syndromes in which dorsal root ganglia and anatomically connected sensory pathways emerge as recurring sites of sensitisation. Pathogenicity depends not only on antibody specificity but also on tissue context and downstream neuroimmune mechanisms, supporting the development of more targeted and mechanism-based therapeutic approaches.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.